- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Dapagliflozin, Placebo for dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 833 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 36
- States / cities
- Little Rock, Arkansas • Encino, California • La Mesa, California + 33 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 104
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Heart Failure, Acute Kidney Injury
- Interventions
- Dapagliflozin 10mg Tab, Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut
- Conditions
- Type 2 Diabetes
- Interventions
- Saxagliptin, Metformin XR, Dapagliflozin, Placebo matching with Dapagliflozin, Placebo matching with Saxagliptin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 80
- States / cities
- Birmingham, Alabama • Homewood, Alabama • Muscle Shoals, Alabama + 73 more
- Conditions
- Heart Failure With Reduced Ejection Fraction (HFrEF)
- Interventions
- Dapagliflozin, Placebo
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 150 Years
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 23
- States / cities
- Alexander City, Alabama • Fairhope, Alabama • Fort Payne, Alabama + 19 more
- Conditions
- Renal Insufficiency, Chronic
- Interventions
- Balcinrenone/dapagliflozin, Dapagliflozin, Placebo matching Dapagliflozin, Placebo matching balcinrenone/dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 2,800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 68
- States / cities
- Huntsville, Alabama • Surprise, Arizona • Tempe, Arizona + 63 more
- Conditions
- Evaluate Ketogenic Stress
- Interventions
- Exenatide/Exenatide extended release, Dapagliflozin, Placebo
- Drug
- Lead sponsor
- University at Buffalo
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Williamsville, New York
- Conditions
- Lewy Body Dementia, Parkinson Disease
- Interventions
- Sitagliptin, Dapagliflozin, Placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 45 Years to 65 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Healthy
- Interventions
- Dapagliflozin, Moxifloxacin, Placebo to match moxifloxacin and dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Dapagliflozin, Insulin, Liraglutide, Dapagliflozin placebo
- Drug
- Lead sponsor
- University at Buffalo
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Chronic Kidney Diseases
- Interventions
- Zibotentan, Dapagliflozin, Placebo, Dapagliflozin and Zibotentan
- Drug
- Lead sponsor
- University Medical Center Groningen
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Weight Loss
- Interventions
- Dapagliflozin, Placebo, Weight maintenance, Ad libitum dietary intake, Dietary restriction
- Drug · Behavioral
- Lead sponsor
- Christopher Bell
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Fort Collins, Colorado
- Conditions
- Physical Activity
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- Christopher Bell
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Fort Collins, Colorado
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 35 Years to 70 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 3
- States / cities
- San Diego, California • Baton Rouge, Louisiana • Philadelphia, Pennsylvania
- Conditions
- Fontan Circulation, Single Ventricle Heart Disease, HFpEF - Heart Failure With Preserved Ejection Fraction
- Interventions
- Dapagliflozin tablet, Placebo Tablet
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Dulaglutide, Placebo, SGLT2 inhibitor, Metformin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 424 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 13
- States / cities
- Encino, California • Huntington Park, California • Los Angeles, California + 9 more
- Conditions
- Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 4,744 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 86
- States / cities
- Fairhope, Alabama • Mobile, Alabama • Sheffield, Alabama + 74 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Dapagliflozin 10 mg, Matching Placebo for Dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 321 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 27
- States / cities
- Huntsville, Alabama • Burbank, California • Chula Vista, California + 22 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Pioglitazone 45 mg, Placebo
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Dapagliflozin, Placebo for dapagliflozin
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 815 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 47
- States / cities
- Concord, California • Fresno, California • Los Angeles, California + 40 more
- Conditions
- Type 2 Diabetes
- Interventions
- Saxagliptin, Dapagliflozin, Metformin IR, Placebo matching with Saxagliptin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Muscle Shoals, Alabama • Mesa, Arizona + 26 more
- Conditions
- Diabetes Mellitus, Type 2, Cardiovascular Diseases
- Interventions
- Dapagliflozin 10mg, Saxagliptin 5mg, Placebo Oral Tablet
- Drug
- Lead sponsor
- Sabyasachi Sen
- Other
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Diabetes Mellitus, Type 2, Endothelial Dysfunction
- Interventions
- Dapagliflozin, Placebo
- Drug · Other
- Lead sponsor
- Boston University
- Other
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Dapagliflozin, Exenatide, Placebo
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Type 2 Diabetes Mellitus, Inadequate Glycaemic Control
- Interventions
- Dapagliflozin, Placebo for Dapagliflozin, Saxagliptin, Placebo for Saxagliptin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 905 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 48
- States / cities
- Saraland, Alabama • Fresno, California • Harbor City, California + 41 more